Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study

Blood

Volumn 102, Issue 3, 2003, Pages 996-999

  Mele, Alfonso ^a   Pulsoni, Alessandro ^b   Bianco, Elvira ^b   Musto, Pellegrino ^b   Szklo, Andrè ^b   Grazia Sanpaolo, Maria ^b   Lannitto, Emilio ^b   De Renzo, Amalia ^b   Martino, Bruno ^b   Liso, Vincenzo ^b   Andrizzi, Cristina ^b   Pusterla, Simona ^b   Dore, Fausto ^b   Maresca, Maddalena ^b   Rapicetta, Maria ^b   Marcucci, Fabrizio ^b   Mandelli, Franco ^b   Franceschi, Silvia ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL ACTIVITY; ARTICLE; B CELL LYMPHOMA; BIRTH; CALCULATION; CANCER CLASSIFICATION; CANCER INVASION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; GEOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HOSPITAL DEPARTMENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK; STANDARDIZATION; STATISTICAL ANALYSIS; VIRUS CARCINOGENESIS;

EID: 0042243586     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3230     Document Type: Article

References (41)

1. Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood. 1994;84:3047-3053.
2. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;19:1490-1495.
3. Ferri C, Caracciolo F, Zignego A, et al. Hepatitis C infection in patients with non-Hodgkin's lymphoma. Br J Haematol. 1994;88:392-394.
4. Mazzaro C, Zagonel V, Monfardini S, et al. Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol. 1996;94:544-550.
5. Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood. 1996;10:4296-4301.
6. Sansonno D, De Vita S, Cornacchiulo V, Carbone A, Boiocchi M, Dammacco F. Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. Blood. 1996;88:4638-4645.
7. Musto P, Dell'Olio M, Carotenuto M, Mangia A, Andriulli A. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? Blood. 1996;88:752-754.
8. Luppi M, Ferrari MG, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia. 1996;10:351-355.
9. De Rosa G, Gobbo ML, De Renzo A, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol. 1997;55:77-82.
10. De Vita S, Zagonel V, Russo A, et al. Hepatitis C virus, non Hodgkin's lymphomas and hepatocellular carcinoma. Br J Cancer. 1998;77:2032-2035.
11. Vallisa D, Bertè R, Rocca A, et al. Association between hepatitis C virus and non-Hodgkin's lymphoma and effects of viral infection on histologic subtype and clinical course. Am J Med. 1999;106: 556-560.
12. Zucca E, Roggeri E, Malgi-Socca N, et al. Prevalence of Helicobacter pylori and hepatitis C virus infection among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica. 2000;85:147-153.
13. Montella M, Crispo A, Frigeri F, et al. HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity Leuk Res. 2001;9:775-781.
14. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127: 423-428.
15. Izumi E, Sasaki R, Tsunoda S, Akutsu M, Okamoto H, Miura Y. B cell malignancy and hepatitis C virus infection. Leukemia. 1997;11:516-518.
16. McColl MD, Tait RC. Hepatitis C virus infection in patients with lymphoproliferative disorders. Br J Haematol. 1996;92:771-772.
17. Hanley J, Jarvis L, Simmonds P, Parker A, Ludlam C. HCV and non-Hodgkin lymphoma [abstract]. Lancet. 1996;347:1339.
18. Ohsawa M, Shingu N, Miwa H, et al. Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection. Int J Cancer. 1999;80:237-239.
19. Collier JD, Zanke B, Moore M, et al. No association between hepatitis C and B-cell lymphoma. Hepatology. 1999;29:1259-1261.
20. Udomsakdi-Auewarakul C, Auewarakul P, Sukpanichnant S, Muangsup W. Hepatitis C virus infection in patients with non-Hodgkin lymphoma in Thailand. Blood. 2000;95:3640-3641.
21. Pioltelli P, Gargantini L, Cassi E, et al. Hepatitis C virus in non-Hodgkin's lymphoma: a reappraisal after a prospective case-control study of 300 patients. Am J Hematol. 2000;64:95-100.
22. Hausfater P, Cacoub P, Sterkers Y, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol. 2001;67:168-171.
23. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
24. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisor Committee Meeting Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
25. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol. 1985;122:904-914.
26. Maio G, D'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol. 2000;33:116-120.
27. Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol. 1999; 37:2371-2372.
28. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874-879.
29. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26:1006-1011.
30. ZignegoAL, Ferri C, Giannini C, Monti M, La Civata L, Careccia G. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996;124:31-34.
31. Andreone P, Gramenzi A, Cursaro C, Bernardi M, Zignego AL. Monoclonal gammopathy in patients with chronic hepatitis C virus infection. Blood. 1996;88:1122-1126.
32. International Agency for Research on Cancer World Health Organization. Cancer Incidence in Five Continents. Vol VII. Lyon, France; IARC Scientific Publications: no. 143; 1997.
33. Gentile G, Mele A, Monarca B, et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case control study. Cancer Epidemiol Biomarkers Prev. 1996; 5:227-230.
34. De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96:3578-3584.
35. L kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998;91: 2433-2442.
36. De Re V, De Vita S, Marzotto A, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer. 2000;87:211-216.
37. Bronowicki JP, Loriot MA, Thiers V, Grignon Y, Zignego AL, Bréchot C. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology. 1998;28:211-218.
38. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology. 2002;294:94-105.
39. Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signalling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem. 2001;276:12140-12146.
40. Manns MP, McHutchison JG, Gordon SC, et al. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
41. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89-94